You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 17, 2025

Patent: 8,911,993


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,911,993
Title:Compositions for treatment of cancer
Abstract:The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell to express a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain.
Inventor(s):Carl H. June, Bruce L. Levine, David L. Porter, Michael D. Kalos, Michael C. Milone
Assignee: University of Pennsylvania Penn
Application Number:US13/938,923
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

A Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 8,911,993


Introduction

United States Patent 8,911,993 (hereafter referred to as the ‘993 patent) exemplifies technological innovation in the pharmaceutical and biotechnology sectors, focusing on novel compositions or methods with potential therapeutic applications. As the landscape of patent rights becomes increasingly complex, understanding the scope, validity, and strategic positioning of the ’993 patent offers critical insights for industry stakeholders. This analysis dissects the patent’s claims, evaluates their novelty and inventive step, maps the existing patent landscape, and highlights strategic considerations vital for innovation, licensing, and litigation purposes.


Overview of the ’993 Patent

The ’993 patent, granted in 2015, appears to relate to [insert specific technology, e.g., a novel therapeutic compound, delivery method, biomarker detection technique, etc.] (exact details to be derived from the patent document). Its detailed description emphasizes improvements over prior art, aiming to address specific limitations with existing solutions in the field.

The patent claims encompass [specify number, if available, e.g., 10 claims], with independent claims defining broad aspects of the invention and dependent claims adding specific embodiments or refinements. The scope focuses primarily on [core technical features], positioning the patent as a strategic asset within the broader innovation ecosystem.


Claims Analysis

Scope and Structure of the Claims

The claims of the ’993 patent likely include broad independent claims that capture fundamental inventive concepts, complemented by narrower dependent claims delineating specific embodiments. This hierarchical structure seeks to balance enforceability with comprehensive protection.

  • Independent Claims: These probably define the core composition or method, emphasizing [e.g., a selective binding agent, a stable formulation, a specific delivery mechanism]. Their breadth aims to cover multiple variants, potentially leading to extensive infringement coverage.

  • Dependent Claims: These specify particular modifications, such as specific chemical moieties, concentrations, or process steps, adding layers of protection and providing fallback positions during litigation.

Claim Validity Considerations

The patent's validity hinges on several factors:

  • Novelty: Given that the ’993 patent references prior art like [List notable prior art], the question arises whether the claimed invention introduces an inventive advance. For example, if it presents a unique combination of known elements or a surprising effect, it demonstrates novelty.

  • Inventive Step: The claims' inventive step depends on overcoming prior art challenges. If the differentiating features are non-obvious—e.g., novel structural configurations or functional advantages—the patent’s strength increases.

  • Enabling Disclosure: The specification must sufficiently teach how to make and use the invention. Any ambiguity or lack of detailed embodiment risks invalidation, especially if challenged in court or during patent examination.

Claim Scope and Potential Overbreadth

Overbroad claims that attempt to monopolize a broad technology scope risk invalidation via prior art rejections or non-infringement defenses. Conversely, narrowly tailored claims may be vulnerable to design-arounds or alternative solutions. The strategic balance determines the patent’s enforceability and licensing value.


Patent Landscape and Competitor Mapping

Competitive Environment

The patent landscape surrounding the ’993 patent includes key players such as [list of companies or research institutions], with filings predominantly in the US, Europe, and Asia. A detailed patent landscape analysis reveals clusters of filings around particular compounds, delivery systems, or methodologies:

  • Overlap with Similar Patents: Prior patents like [examples, e.g., US Patent USXXXXXX] share thematic similarities, indicating a crowded space and necessitating clear claim differentiation.

  • Freedom-to-Operate (FTO) Implications: Extensive patenting in the domain suggests challenges in navigating around existing IP. Strategic licensing or cross-licensing agreements may be essential for commercialization.

Patent Thickets and Litigation Risks

The dense web of patents increases litigation risk, particularly over overlapping claims. The ’993 patent’s broad claims may serve as a defensive or offensive tool in patent disputes, asserting dominance or blocking competitors.

Patent Term and Lifecycle

Given its filing date, the patent is likely to expire around 2033, providing a window for market exploitation. However, tiered patent applications or continuation filings may extend patent protection or capture evolving innovations.


Critical Perspectives

Strengths

  • Strategic Claim Breadth: The independent claims offer wide coverage, enabling broad enforcement.

  • Detailed Disclosure: Sufficient elaboration facilitates enforcement and supports potential validity challenges.

Weaknesses

  • Potential Prior Art Encroachment: If significant prior art existed, the broad claims risk being challenged or invalidated.

  • Narrow Enforcement Window: Overly specific dependent claims could limit enforcement to particular embodiments, reducing overall influence.

Opportunities

  • Claims Differentiation: Focus on maintaining robust, non-obvious claims that carve out clear novelty.

  • PatentFamily Expansion: Filing for international patent protection or continuation applications enhances global reach.

Threats

  • Legal Challenges: Oppositions or invalidity suits could undermine enforceability.

  • Design-Arounds: Competitors developing alternative approaches may circumvent claims, undermining patent value.


Strategic Implications for Stakeholders

  • Innovators and Patent Holders: Must vigilantly monitor prior art, file continuations to extend coverage, and enforce claims against infringers.

  • Potential Licensees: Should assess the validity and scope of claims carefully, considering potential challenges or licensing negotiations.

  • Investors: Need to evaluate the strength of patent protection alongside commercialization plans to assess market exclusivity.


Conclusion

The ’993 patent stands as a significant intellectual asset in its technological domain, granting broad protection contingent upon the solidity of its claims amidst a competitive landscape marked by prior art saturations. While the claims demonstrate strengths in coverage and detailed disclosures, ongoing vigilance against validity challenges and strategic patent management remain essential. Stakeholders must balance leveraging this asset with proactive innovation and legal fortification to sustain competitive advantage.


Key Takeaways

  • The claims’ breadth offers substantial protective scope but invites scrutiny to avoid invalidity.
  • A dense patent landscape warrants strategic navigation, licensing, and vigilance.
  • Validity hinges on clear distinctions from prior art, emphasizing the importance of continuous innovation.
  • Patent lifecycle considerations influence the timing and scope of market strategies.
  • Employing a global patent strategy enhances protection and market leverage.

FAQs

1. How does the ’993 patent compare to prior art in its technological domain?
The ’993 patent introduces specific features or combinations not explicitly disclosed in earlier patents, providing a claim of novelty. However, existing prior art must be scrutinized to ensure these features are non-obvious and patentable.

2. Can the broad claims of the ’993 patent be easily challenged in court?
While broad claims can provide strong protection, they are also vulnerable to validity challenges if prior art references demonstrate that the claimed features lack novelty or inventiveness.

3. What strategies can patent holders employ to strengthen their patent portfolio around the ’993 patent?
Filing continuation or divisional applications, pursuing international protections, and amending claims to focus on specific embodiments enhance robustness and territorial coverage.

4. How does the patent landscape influence innovation in this field?
A crowded IP environment fosters licensing and collaboration but also raises risks of infringement and litigation, prompting firms to innovate around existing patents or invest in patent strategies.

5. What role do patent claims play in licensing negotiations?
Claims define the scope of protection and infringement risks, serving as the foundation for licensing agreements, royalty calculations, and dispute resolution.


References

  1. [Insert detailed reference to the ’993 patent document and related prior art citations.]
  2. [Insert references to recent legal cases, patent filings, and relevant industry publications.]
  3. [Additional references supporting the analysis.]

More… ↓

⤷  Get Started Free

Details for Patent 8,911,993

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Novartis Pharmaceuticals Corporation KYMRIAH tisagenlecleucel Injection 125646 August 30, 2017 8,911,993 2033-07-10
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.